PATIENT NAME: RAM CHANDRA MEENA

CODE/NAME & ADDRESS: C000138404

PROVISIONAL REPORT

CLIENT PATIENT ID: 012312090032

AGE/SEX: 58 Years Male

PATIENT ID: 012312090032

RECEIVED: 09/12/2023 14:47:48

REPORTED: 10/12/2023 15:23:31

Test Report Status F	<u>Final</u>	Results	Biological Reference Interval	Units
----------------------	--------------	---------	-------------------------------	-------

HAEMATOLOGY - CBC					
MEDI WHEEL FULL BODY HEALTH CHECK UP AI	BOVE 40 MALE				
BLOOD COUNTS, EDTA WHOLE BLOOD					
HEMOGLOBIN (HB)  METHOD: CYANIDE FREE DETERMINATION	14.9	13.0 - 17.0	g/dL		
RED BLOOD CELL (RBC) COUNT  METHOD: ELECTRICAL IMPEDANCE	4.65	4.5 - 5.5	mil/µL		
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.80	4.0 - 10.0	thou/µL		
PLATELET COUNT  METHOD: ELECTRONIC IMPEDANCE	239	150 - 410	thou/μL		
RBC AND PLATELET INDICES					
HEMATOCRIT (PCV)  METHOD: CALCULATED PARAMETER	44.1	40 - 50	%		
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	95.0	83 - 101	fL		
MEAN CORPUSCULAR HEMOGLOBIN (MCH)  METHOD: CALCULATED PARAMETER	32.1 High	27.0 - 32.0	pg		
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	33.8	31.5 - 34.5	g/dL		
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	11.6	11.6 - 14.0	%		
MENTZER INDEX	20.4				
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	8.3	6.8 - 10.9	fL		
WBC DIFFERENTIAL COUNT					
NEUTROPHILS  METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	67	40 - 80	%		
LYMPHOCYTES  METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	25	20 - 40	%		
MONOCYTES	06	2 - 10	%		

Page 1 Of 15





View Details

View Report

**PATIENT NAME: RAM CHANDRA MEENA REF. DOCTOR: SELF** CODE/NAME & ADDRESS: C000138404 ACCESSION NO: 0251WL000698 AGE/SEX :58 Years DRAWN :09/12/2023 09:44:00 PATIENT ID : RAMCM091265251 PROVISIONAL REPORT CLIENT PATIENT ID: 012312090032 RECEIVED: 09/12/2023 14:47:48 ABHA NO REPORTED :10/12/2023 15:23:31

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS	02	1 - 6	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
BASOPHILS	00	0 - 2	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	3.22	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	1.2	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.29	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.10	0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.7		

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading

to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Page 2 Of 15





View Report



PROVISIONAL REPORT | PATIENT ID : RAMCM091265251 | DRAWN :09/12/2023 09:44:00 | CLIENT PATIENT ID: 012312090032 | RECEIVED :09/12/2023 14:47:48

ABHA NO : REPORTED :10/12/2023 15:23:31

Test Report Status <u>Final</u> Results Biological Reference Interval Units

### **HAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 4.9 Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4
Diabetics: > or = 6.5
Therapeutic goals: < 7.0
Action suggested: > 8.0
(ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 93.9 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Page 3 Of 15





View Details

View Repor

**REF. DOCTOR: SELF PATIENT NAME: RAM CHANDRA MEENA** CODE/NAME & ADDRESS: C000138404 ACCESSION NO: 0251WL000698 AGE/SEX :58 Years :09/12/2023 09:44:00 PATIENT ID : RAMCM091265251 DRAWN PROVISIONAL REPORT CLIENT PATIENT ID: 012312090032 RECEIVED: 09/12/2023 14:47:48 REPORTED :10/12/2023 15:23:31 ABHA NO

**Test Report Status** Results **Biological Reference Interval Final** Units

### **MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD**

mm at 1 hr E.S.R 09

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.
- Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
   eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

#### HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
  c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

#### REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Page 4 Of 15





View Report



PROVISIONAL REPORT | PATIENT ID : RAMCM091265251 | DRAWN :09/12/2023 09:44:00 | CLIENT PATIENT ID: 012312090032 | RECEIVED :09/12/2023 14:47:48

ABHA NO : REPORTED :10/12/2023 15:23:31

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **IMMUNOHAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD** 

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Page 5 Of 15





View Details

View Repor

CODE/NAME & ADDRESS: C000138404 ACCESSION NO: 0251WL000698 AGE/SEX :58 Years

PATIENT ID DRAWN :09/12/2023 09:44:00 : RAMCM091265251 PROVISIONAL REPORT CLIENT PATIENT ID: 012312090032 RECEIVED: 09/12/2023 14:47:48

ABHA NO REPORTED :10/12/2023 15:23:31

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

**BIOCHEMISTRY** 

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 86 74 - 99 mg/dL

METHOD: GLUCOSE OXIDASE

**GLUCOSE, POST-PRANDIAL, PLASMA** 

70 - 140 PPBS(POST PRANDIAL BLOOD SUGAR) mg/dL 108

METHOD: GLUCOSE OXIDASE

LIPID PROFILE WITH CALCULATED LDL

< 200 Desirable mg/dL CHOLESTEROL, TOTAL 187

200 - 239 Borderline High

>/= 240 High METHOD: CHOLESTEROL OXIDASE

160 High mg/dL TRIGLYCERIDES < 150 Normal

150 - 199 Borderline High

200 - 499 High

>/=500 Very High METHOD: LIPASE/GPO-PAP NO CORRECTION

HDL CHOLESTEROL 77 High < 40 Low mg/dL

>/=60 High

METHOD: DIRECT CLEARANCE METHOD CHOLESTEROL LDL 78

< 100 Optimal mg/dL

100 - 129

Near optimal/ above optimal

130 - 159 Borderline High

160 - 189 High >/= 190 Very High

NON HDL CHOLESTEROL 110 Desirable: Less than 130 mg/dL

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220METHOD: CALCULATED PARAMETER

Page 6 Of 15





PATIENT NAME: RAM CHANDRA MEENA	REF. DOCTOR :	: SELF
CODE/NAME & ADDRESS: C000138404	ACCESSION NO: 0251WL000698	AGE/SEX :58 Years Male
PROVICTORIAL PEROPT	РАПЕНТ ID : RAMCM091265251	DRAWN :09/12/2023 09:44:00
PROVISIONAL REPORT	CLIENT PATIENT ID: 012312090032	RECEIVED : 09/12/2023 14:47:48
	ABHA NO :	REPORTED :10/12/2023 15:23:31

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
VERY LOW DENSITY LIPOPROTEIN	32.0 High	= 30.0 mg/dL</td
CHOL/HDL RATIO	2.4 Low	3.3 - 4.4  Low Risk 4.5 - 7.0  Average Risk 7.1 - 11.0  Moderate Risk > 11.0  High Risk
LDL/HDL RATIO	1.0	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

#### Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

	TESC V D ( MINETOSKETONE CHI GIOVIISCUM) GI			
Risk Category				
Extreme risk group		A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk;	group or recurrent ACS (within 1 year) despite LDL-C < or =		
	50 mg/dl or polyvascular disease			
Very High Risk	Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.		
	Familial Homozygous Hypercholesterolemi			
High Risk	Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ			
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors			
Low Risk	0-1 major ASCVD risk factors			
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	actors		
Age > or = 45 years in males and > or = 55 years in females     Current Cigarette smoking or tobacco use				
Family history of premature ASCVD     4. High blood pressure				
5. Low HDL				

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		

Page 7 Of 15





/iew Details

View Report



PATIENT NAME: RAM CHANDRA MEENA	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138404	ACCESSION NO: 0251WL000698	AGE/SEX :58 Years Male
DDGUTGTONAL DEDGET	PATIENT ID : RAMCM091265251	DRAWN :09/12/2023 09:44:00
PROVISIONAL REPORT	CLIENT PATIENT ID: 012312090032	RECEIVED : 09/12/2023 14:47:48
	ABHA NO :	REPORTED :10/12/2023 15:23:31

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
--------------------	--------------	---------	-------------------------------------

Extreme Risk Group Category B	<or 30<="" =="" th=""><th><or 60<="" =="" th=""><th>&gt; 30</th><th>&gt;60</th></or></th></or>	<or 60<="" =="" th=""><th>&gt; 30</th><th>&gt;60</th></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

### LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.79	0 - 1	mg/dL
METHOD : DIAZO WITH SULPHANILIC ACID	0.24	2.22 2.25	
BILIRUBIN, DIRECT	0.24	0.00 - 0.25	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID	0.55	0.1 - 1.0	ma/dl
BILIRUBIN, INDIRECT	0.55	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	7.9	6.4 - 8.2	g/dL
METHOD: BIURET REACTION, END POINT	7.9	0.4 - 6.2	g/uL
ALBUMIN	4.7 High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN	3.2	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	42 High	0 - 37	U/L
METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	21	0 - 40	U/L
METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C	/		
ALKALINE PHOSPHATASE	78	39 - 117	U/L
METHOD : AMP OPTIMISED TO IFCC 37° C	0.5	44 50	
GAMMA GLUTAMYL TRANSFERASE (GGT)	35	11 - 50	U/L
METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC) 3		222	117
LACTATE DEHYDROGENASE	341	230 - 460	U/L
DI COD LIDEA NITTOCEN (DUN) CECUM			
BLOOD UREA NITROGEN (BUN), SERUM			

8

Page 8 Of 15



5.0 - 18.0



/iew Details

View Repor

BLOOD UREA NITROGEN

METHOD: UREASE KINETIC



mg/dL

PATIENT NAME: RAM CHANDRA MEENA	REF. DOCTOR:	SELF
CODE/NAME & ADDRESS : C000138404	ACCESSION NO: 0251WL000698	AGE/SEX :58 Years Male
DDOVICIONAL DEDORT	PATIENT ID : RAMCM091265251	DRAWN :09/12/2023 09:44:00
PROVISIONAL REPORT	CLIENT PATIENT ID: 012312090032	RECEIVED : 09/12/2023 14:47:48
	ABHA NO :	REPORTED :10/12/2023 15:23:31
Test Report Status <u>Final</u>	Results Biologica	l Reference Interval Units

CREATININE, SERUM CREATININE	1.02	0.8 - 1.3	mg/dL
METHOD: ALKALINE PICRATE NO DEPROTEINIZATION			-
BUN/CREAT RATIO BUN/CREAT RATIO METHOD: CALCULATED PARAMETER	7.84		
URIC ACID, SERUM URIC ACID METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE	5.9	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM  TOTAL PROTEIN  METHOD: BIURET REACTION, END POINT	7.9	6.4 - 8.3	g/dL
ALBUMIN, SERUM ALBUMIN	4.7 High	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN	<b></b>	3.0 4.4	9, 42
GLOBULIN GLOBULIN	3.2	2.0 - 4.1	g/dL

**ELECTROLYTES (NA/K/CL), SERUM** 

Page 9 Of 15





View Details

View Report

**PATIENT NAME: RAM CHANDRA MEENA REF. DOCTOR: SELF** CODE/NAME & ADDRESS: C000138404 ACCESSION NO: 0251WL000698 AGE/SEX :58 Years PATIENT ID DRAWN :09/12/2023 09:44:00 : RAMCM091265251 PROVISIONAL REPORT CLIENT PATIENT ID: 012312090032 RECEIVED: 09/12/2023 14:47:48 ABHA NO REPORTED :10/12/2023 15:23:31

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
SODIUM, SERUM	140.0	137 - 145	mmol/L
METHOD: ION-SELECTIVE ELECTRODE			
POTASSIUM, SERUM	4.05	3.6 - 5.0	mmol/L
METHOD: ION-SELECTIVE ELECTRODE			
CHLORIDE, SERUM	101.4	98 - 107	mmol/L
METHOD: ION-SELECTIVE ELECTRODE			

#### Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased In: Yomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renat failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourinquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

#### Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within  $individuals. Thus, \ glycosylated \ hemoglobin (HbA1c) \ levels \ are \ favored \ to \ monitor \ glycemic \ control.$ 

Page 10 Of 15





View Report

**PATIENT NAME: RAM CHANDRA MEENA REF. DOCTOR: SELF** CODE/NAME & ADDRESS: C000138404 ACCESSION NO: 0251WL000698 AGE/SEX :58 Years :09/12/2023 09:44:00 PATIENT ID : RAMCM091265251 DRAWN PROVISIONAL REPORT CLIENT PATIENT ID: 012312090032 RECEIVED: 09/12/2023 14:47:48 REPORTED :10/12/2023 15:23:31 ABHA NO

**Test Report Status** Results **Biological Reference Interval Final** Units

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. **AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured

clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

**GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein,is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Mysthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Page 11 Of 15





View Details

View Report

PROVISIONAL REPORT PATIENT ID : RAMCM091265251 DRAWN

CLIENT PATIENT ID: 012312090032 RECEIVED : 09/12/2023 14:47:48

ABHA NO : REPORTED :10/12/2023 15:23:31

:09/12/2023 09:44:00

Test Report Status Final Results Biological Reference Interval Units

**CLINICAL PATH - URINALYSIS** 

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR SAMPLE NOT RECEIVED

Page 12 Of 15





View Details

View Repor



PROVISIONAL REPORT | PATIENT ID : RAMCM091265251 | DRAWN :09/12/2023 09:44:00 | CLIENT PATIENT ID: 012312090032 | RECEIVED :09/12/2023 14:47:48

ABHA NO : REPORTED :10/12/2023 15:23:31

Test Report Status <u>Final</u> Results Biological Reference Interval Units

**CLINICAL PATH - STOOL ANALYSIS** 

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD : GROSS EXAMINATION

Page 13 Of 15





View Details

View Repor



 PATIENT NAME : RAM CHANDRA MEENA
 REF. DOCTOR : SELF

 CODE/NAME & ADDRESS : C000138404
 ACCESSION NO : 0251WL000698
 AGE/SEX : 58 Years Male

 PROVISIONAL REPORT
 PATIENT ID : RAMCM091265251 CLIENT PATIENT ID: 012312090032 ABHA NO : REPORTED : 10/12/2023 14:47:48

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **SPECIALISED CHEMISTRY - HORMONE**

## MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

#### THYROID PANEL, SERUM

ТЗ	99.93	60.0 - 181.0	ng/dL
METHOD: CHEMILUMINESCENCE			
T4	7.30	4.5 - 10.9	μg/dL
METHOD: CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1.329	0.550 - 4.780	μIU/mL
METHOD: CHEMILUMINESCENCE			

#### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Page 14 Of 15





View Details

View Report

PATIENT NAME: RAM CHANDRA MEENA

CODE/NAME & ADDRESS: C000138404

PATIENT ID: RAMCM091265251

CLIENT PATIENT ID: 012312090032

ABHA NO: REPORTED: 10/12/2023 15:23:31

Test Report Status <u>Final</u> Results Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor		
7	Low	Low	Low	Low	ow (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent		
					treatment for Hyperthyroidism		
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness		
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies		

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

\*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession

### **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

#### **Agilus Diagnostics Limited**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 15 Of 15





iew Details

View Report



# **Aakriti Labs**

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.sakritilabs.com

CIN NO.: U85195RJ2084PTC019563



Name : Mr. RAM CHNADR AMEENA

Age/Gender: 58 Y/Male

Patient ID : 012312090032

BarcodeNo :10107006

Referred By : Self

Registration No: 71043

Registered

: 09/Dec/2023 09:44AM

Analysed

: 09/Dec/2023 03:35PM

Reported

: 09/Dec/2023 03:35PM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

## DIGITAL X-RAY CHEST PA VIEW

Unfolding of arch of aorta is seen.

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits,

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

\*\*\* End Of Report \*\*\*

Page 1 of 1



Dr. Negra Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853

ALPL policy mandates the film records to be maintained for a period of 3 months only. Kindly collect the films before this period.



# Aakriti Lahs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

PATIENT NAME: MR RAM CHANDRA MEENA

AGE & SEX: 58Y/M

REF. by: MEDI WHEEL

DATE: 09.12.2023

USG: WHOLE ABDOMEN (Male)

LIVER

: Is normal in size, shape and echogenecity. The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen.

Portal vein diameter and common bile duct appear normal.

GALL

: Is normal in size, shape and echotexture. Walls are smooth and BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. : Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture,

measures: 45 x 29 x 29 mm, wt: 20 gms.

Its capsule is intact and no evidence of focal lesion.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity. NO evidence of lymphadenopathy or mass lesion in retroperitoneum. : Visualized bowel loop appear normal Great vessels appear normal.

IMPRESSION:- NORMAL STUDY

DR NEERA MEHTA MBBS, DMRD RMCNO.005807/14853



# Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	MR RAM CHANDRA MEENA	AGE	58Y	SEX	MALE
REF BY	MEDI WHEEL	DATE	9/12/2023	REG NO	

### ECHOCARDIOGRAM REPORT

WINDOW- PO	OR/ADEQU	JATE/GC	ODVALVE					
MITRAL	AL NORMA			TRICUSPID		NORMA	NORMAL	
AORTIC	1	NORMA		PULMONARY	Y	NORMA	(L	
2D/M-MOD	11-							
IVSD mm	14.2		IVS5 mm	16.6	AORTA	mm	n 28.4	
LVID mm	47.4		LVIS mm	38.6	LA mm	1	2	
LVPWD mm	16.9		LVPWS mm	16.2	EF%		35-40%	
CHAMBERS								
LA		NO	RMAL	RA		NOF	RMAL	
LV		NO	RMAL	RV		NOF	RMAL	
PERICARDIUM		NO	RMAL					
DOPPLER STUI	DY MITRAL		110000000000000000000000000000000000000					
PEAK VELOCITY	Y m/s E/A	0.7	5/0.98	PEAK GRADIANT MmHg			1.0	
MEAN VELOCIT	TY m/s			MEAN GRA	MEAN GRADIANT MmHg			
MVA cm2 (PLANITMETERY)		(Y)		MVA cm2 (	MVA cm2 (PHT)			
MR		M	DDERATE					
AORTIC		- 10		1/1/				
PEAK VELOCITY	Y m/s	28.	7	PEAK GRAD	DIANT MmHg			
MEAN VELOCITY m/s				MEAN GRA	MEAN GRADIANT MmHg			
AR		MI	LD	1				
TRICUSPID		- 1	1	4.6				
PEAK VELOCITY m/s		0.7	3 \\//	PEAK GRADIANT MmHg				
MEAN VELOCIT	ΓV m/s		VV	MEAN GRA	MEAN GRADIANT MMHg			
TR MILD		PASP mmHg 35+RAP			RAP			
PULMONARY				A F I I	1 1 1			
PEAK VELOCITY m/s		1.4	2	PEAK GRAD	PEAK GRADIANT MmHg			

MEAN GRADIANT MMHg

RVEDP mmHg

## **IMPRESSION**

PR

MEAN VELOCITY m/s

- GLOBAL HYPOKINESIA WITH REGIONAL VARIATION
- MODERATE LV DYSFUNCTION, LVEF 35-40%
- MODERATE MR
- MILD AR, MILD TR (RVSP=35+RAP mm of Hg)
- CONCENTRIC LVH, DRA +NT
- INTACT IAS / IVS

Cardiologist

